Entrada Presents New Data

Entrada Therapeutics announced encouraging new data on their exon 44 skipping program following their presentation at TIDES USA 2022. CureDuchenne provided funding to Entrada last year as part of their Series B financing to advance its lead Duchenne exon-skipping oligonucleotide program to the clinic.

We’re excited to hear they are on pace to submit an IND to the FDA in Q4 2022.